|Articles|August 27, 2021

AJMC® in the Press, August 27, 2021

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by Wyoming News Now referenced an article published on AJMC.com, the website of The American Journal of Managed Care^® (AJMC^®). The article, “A Timeline of COVID-19 Developments in 2020,” provides an overview of how the COVID-19 pandemic evolved and progressed last year.

A piece by VeryWellHealth featured an interview with Anthony Hagen, senior editor of AJMC®’s sister site The Center for Biosimilars^®. In the piece, Hagen discussed how in the absence of biosimilar competition, originator companies are in some cases able to raise their drug prices to exorbitant levels.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

In 188 patients with upper extremity soft tissue sarcoma, the best machine learning models had a C-index of 0.79 for local recurrence, 0.67 for metastasis, and 0.75 for survival. | Image credit: Dr_Microbe - stock.adobe.com

November 13th, 2026

Machine Learning Models Comparable to Nomograms in Upper Extremity Sarcoma

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

November 13th, 2026

AJMC® in the Press, November 13, 2026

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Lady having a respiratory exacerbation. | Image credit: @RFBSIP_AdobeStock.jpeg

November 12th, 2026

Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Menstruation Period Accessories | Image credit: Atlas - stock.adobe.com

November 12th, 2026

Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

November 12th, 2026

Commentary Warns Census Race Question Removal Could Create Data Gap

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

A review of about 58 patients with MDS or MPN found SGLT2 inhibitors may raise hemoglobin in anemia but could drive erythrocytosis in non-anemic subtypes. | Image credit: mdaros - stock.adobe.com

November 12th, 2026

SGLT2 Inhibitors Tied to Hemoglobin Gains in MDS, Myelofibrosis Anemia

SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.